What Aiolos Bio does

Aiolos Bio is a clinical-stage biopharmaceutical company founded in 2023 and headquartered in San Francisco that develops monoclonal antibody therapies for respiratory and immunology indications. The company's lead asset, AIO-001, is an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody licensed on an exclusive basis from Jiangsu Hengrui Pharmaceuticals for all territories outside greater China. AIO-001's differentiated pharmacokinetic profile supports a twice-yearly dosing schedule, addressing the chronic adherence burden associated with existing biologic therapies for severe asthma.

AIO-001 is being developed as a multi-indication asset. The lead program targets moderate-to-severe asthma and is in Phase 2 development, while exploratory work is underway in chronic obstructive pulmonary disease (COPD) and chronic spontaneous urticaria (CSU). The molecule has already been administered to more than 100 patients in prior Hengrui-conducted clinical work, providing a meaningful human safety and pharmacokinetic dataset for the US/EU development pathway. The asset was in-licensed alongside a $245 million Series A financing closed in October 2023 — one of the largest biotech Series A rounds of that year — from a syndicate comprising Atlas Venture, Bain Capital Life Sciences, Forbion Capital Partners, RA Capital Management, and Sofinnova Investments.

Aiolos Bio is pre-revenue and monetizes through future product commercialization post-regulatory approval rather than current sales. The company's leadership includes co-founder and CEO Khurem Farooq and co-founder Ashley Taylor. Operating model is a capital-intensive clinical development organization, with current spending focused on Phase 2 execution in asthma, exploratory work in COPD and CSU, and buildout of the US/EU development infrastructure required for a global regulatory filing.

Name

Aiolos Bio

Legal name

Aiolos Bio

Website

https://aiolosbio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, a twice-yearly anti-TSLP monoclonal antibody in-licensed from Hengrui Pharmaceuticals, for severe asthma (Phase 2) plus exploratory COPD and CSU programs.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals (Respiratory and Inflammatory Therapeutics)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Monoclonal antibody therapy
• Respiratory disease treatment
• Anti-TSLP antibody
• Inflammatory disease therapy
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody targeting severe asthma, COPD, and chronic spontaneous urticaria (CSU). The asset was in-licensed from Jiangsu Hengrui Pharmaceuticals with exclusive development rights outside of greater China and has been tested in over 100 patients. AIO-001 is designed for twice-yearly dosing, and the company plans to advance it through Phase 2 clinical trials.

Product overview

Aiolos Bio is a biopharmaceutical company focused on developing AIO-001, an anti-TSLP monoclonal antibody for respiratory and inflammatory conditions. The company launched in October 2023 with $245 million Series A funding, one of the largest biotech Series A rounds that year, to advance AIO-001 into Phase 2 clinical trials for severe asthma and explore its potential for COPD and CSU.

Differentiator

Problem solved

Functional benefit

Products and services

• AIO-001 (Anti-TSLP Antibody)

Quantifiable outcome

• Tested in over 100 patients with promising results supporting continued clinical development

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Jiangsu Hengrui PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 24 October 2023Aiolos Bio acquired exclusive development rights for AIO-001 (anti-TSLP antibody) outside of greater China from Jiangsu Hengrui Pharmaceuticals. This licensing arrangement enabled Aiolos Bio to launch with $245 million Series A funding to advance the drug candidate through Phase 2 clinical trials for severe asthma and explore additional indications including COPD and chronic spontaneous urticaria.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Regeneron: Regeneron co-developed Dupixent with Sanofi, the leading biologic in severe asthma and CSU. The drug competes head-to-head with the indications Aiolos Bio is pursuing.
• Sanofi: Sanofi co-markets Dupixent (dupilumab) with Regeneron, approved in both severe asthma and chronic spontaneous urticaria—directly overlapping Aiolos Bio's lead and exploratory indications and setting the efficacy bar AIO-001 must beat.
• GSK: GSK markets Nucala (mepolizumab) and other respiratory biologics, including programs targeting TSLP-related inflammation. It is a broad incumbent in the respiratory/inflammation therapeutic area where Aiolos Bio competes.
• Roche: Roche co-markets Xolair (omalizumab) with Novartis, approved for chronic spontaneous urticaria—one of Aiolos Bio's exploratory indications. It is a direct competitor in the CSU indication.
• Novartis: Novartis co-markets Xolair with Roche (relevant to CSU) and has a broader respiratory portfolio, making it a broad incumbent whose commercial footprint competes with AIO-001's potential launch.
• Teva Pharmaceutical Industries: Teva maintains a respiratory franchise (including severe asthma and COPD products) and represents a broad incumbent competitor whose commercial reach could affect AIO-001's uptake trajectory.

Direct peers

• AstraZeneca: AstraZeneca co-developed and commercializes Tezspire (tezepelumab) with Amgen—an anti-TSLP antibody already approved for severe asthma. It is the most direct therapeutic and mechanistic competitor to Aiolos Bio's AIO-001.
• Amgen: Amgen originally developed tezepelumab (now marketed as Tezspire with AstraZeneca), the only approved anti-TSLP antibody for severe asthma. It is the closest mechanistic competitor to AIO-001.

Emerging players

• Theravance Biopharma: Theravance Biopharma is a clinical-stage company focused on respiratory diseases, sharing Aiolos Bio's therapeutic area focus on respiratory inflammation and offering a comparable development-stage peer for capital and pipeline benchmarking.
• Connect Biopharma: Connect Biopharma is a clinical-stage immunology company developing therapies for inflammatory diseases, providing a useful emerging-stage peer for comparison of capital efficiency and clinical execution in immunology-focused biotechs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aiolos-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aiolos Bio